Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut
- PMID: 12364300
- PMCID: PMC128373
- DOI: 10.1136/bmj.325.7367.740
Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut
Abstract
Objective: To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut.
Design: Natural experiment comparing two fixed cohorts from 1987 to 1997.
Setting: Seattle-Puget Sound and Connecticut surveillance, epidemiology, and end results areas.
Participants: Population based cohorts of male Medicare beneficiaries aged 65-79 drawn from the Seattle (n=94 900) and Connecticut (n=120 621) areas.
Main outcome measures: Rates of screening for prostate cancer, treatment with radical prostatectomy and external beam radiotherapy, and prostate cancer specific mortality.
Results: The prostate specific antigen testing rate in Seattle was 5.39 (95% confidence interval 4.76 to 6.11) times that of Connecticut, and the prostate biopsy rate was 2.20 (1.81 to 2.68) times that of Connecticut during 1987-90. The 10 year cumulative incidences of radical prostatectomy and external beam radiotherapy up to 1996 were 2.7% and 3.9% for Seattle cohort members compared with 0.5% and 3.1% for Connecticut cohort members. The adjusted rate ratio of prostate cancer mortality up to 1997 was 1.03 (0.95 to 1.11) in Seattle compared with Connecticut.
Conclusion: More intensive screening for prostate cancer and treatment with radical prostatectomy and external beam radiotherapy among Medicare beneficiaries in the Seattle area than in the Connecticut area was not associated with lower prostate cancer specific mortality over 11 years of follow up.
Figures
Comment in
-
Prostate specific antigen testing for prostate cancer.BMJ. 2002 Oct 5;325(7367):725-6. doi: 10.1136/bmj.325.7367.725. BMJ. 2002. PMID: 12364286 Free PMC article. No abstract available.
-
Screening populations at low risk carries high risks.BMJ. 2003 Jan 4;326(7379):53. doi: 10.1136/bmj.326.7379.53. BMJ. 2003. PMID: 12511476 Free PMC article. No abstract available.
Similar articles
-
Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up.J Gen Intern Med. 2008 Nov;23(11):1809-14. doi: 10.1007/s11606-008-0785-8. Epub 2008 Sep 16. J Gen Intern Med. 2008. PMID: 18795372 Free PMC article.
-
Changes in prostate cancer incidence and treatment in USA.Lancet. 1994 Jan 29;343(8892):251-4. doi: 10.1016/s0140-6736(94)91109-6. Lancet. 1994. PMID: 7905093
-
The role of increasing detection in the rising incidence of prostate cancer.JAMA. 1995 Feb 15;273(7):548-52. JAMA. 1995. PMID: 7530782
-
Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2018 May 8;319(18):1914-1931. doi: 10.1001/jama.2018.3712. JAMA. 2018. PMID: 29801018 Review.
-
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.Prescrire Int. 2012 Oct;21(131):242-8. Prescrire Int. 2012. PMID: 23185849 Review.
Cited by
-
Follow-Up of Men Who Have Undergone Focal Therapy for Prostate Cancer with HIFU-A Real-World Experience.J Clin Med. 2023 Nov 14;12(22):7089. doi: 10.3390/jcm12227089. J Clin Med. 2023. PMID: 38002699 Free PMC article.
-
Prostate cancer mortality in areas with high and low prostate cancer incidence.J Natl Cancer Inst. 2014 Mar;106(3):dju007. doi: 10.1093/jnci/dju007. Epub 2014 Mar 7. J Natl Cancer Inst. 2014. PMID: 24610909 Free PMC article.
-
The cost implications of prostate cancer screening in the Medicare population.Cancer. 2014 Jan 1;120(1):96-102. doi: 10.1002/cncr.28373. Epub 2013 Oct 4. Cancer. 2014. PMID: 24122801 Free PMC article.
-
Understanding of regional variation in the use of surgery.Lancet. 2013 Sep 28;382(9898):1121-9. doi: 10.1016/S0140-6736(13)61215-5. Lancet. 2013. PMID: 24075052 Free PMC article. Review.
-
The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):56-61. doi: 10.1093/gerona/gls135. Epub 2012 May 4. J Gerontol A Biol Sci Med Sci. 2013. PMID: 22562961 Free PMC article.
References
-
- Potosky A, Miller B, Albertsen P, Kramer B. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–552. - PubMed
-
- Ries L, Eisner M, Kosary C, Hankey B, Miller BA, Clegg L, et al. SEER cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute; 2000.
-
- Tarone R, Chu K, Brawley O. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167–170. - PubMed
-
- Hankey B, Feuer E, Clegg L, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series: interpreting trends in prostate cancer—part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91:1017–1024. - PubMed
-
- Feuer E, Merrill R, Hankey B. Cancer surveillance series: interpreting trends in prostate cancer—part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst. 1999;91:1025–1032. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical